Skip to content
RxMonitor home

Medication

Riva-Letrozole

DIN 02398656 · Laboratoire Riva Inc. Likely a generic

What it is

Active ingredients
Form and route
Tablet · Oral
Schedule
PRESCRIPTION
Authorised since
2014-02-11

Source: Health Canada — Drug Product Database. Data current as of 2026-08-12.

Products with the same active ingredient

Grouped by Health Canada’s active-ingredient group number. Products in a group do not always share a strength — check the strength above against your own. Sharing an active ingredient does not mean two products can be substituted for each other: whether a substitution is permitted is a provincial decision, and this page does not show it. Ask a pharmacist.

Ontario Drug Benefit coverage

As of 31 July 2026

General benefit Part III-A

Ontario lists this product as a general benefit under the Ontario Drug Benefit program — Part III-A of the Formulary/CDI. For someone eligible for ODB, it is covered without a drug-specific approval.

What ODB pays per unit
$1.3780

This is what the Ontario Drug Benefit program reimburses a pharmacy for one unit, as of 31 July 2026. A deductible and a co-payment sit on top of it and differ by program — ODB, the Trillium Drug Program and the seniors co-payment each work differently — so it is not the figure anyone is charged at a counter. It also says nothing about private, workplace or federal coverage.

Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.

Products Ontario considers interchangeable

As of 31 July 2026

Ontario groups these products together at 2.5mg Tab and will substitute one for another at a pharmacy counter in Ontario.

Ontario lists 6 further products in this group that are not currently marketed in Canada. They are not shown.

This is Ontario’s designation, under the Ontario Drug Benefit program, and it applies in Ontario. It is a different statement from the same-active-ingredient list above, which is Health Canada’s grouping and carries no substitution meaning at all. No other province’s rules are shown on this page, and a designation here is not a recommendation to switch — that is a conversation with a pharmacist or prescriber.

Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.

How it is classified

Anatomical main group
Antineoplastic and immunomodulating agents
ATC code
L02BG04

The Anatomical Therapeutic Chemical code records the body system a medicine acts on and its chemical grouping. It is not a statement of what this medication treats, and nothing on this page is. For the full classification of L02BG04, see the WHO ATC/DDD Index.

Recalls and safety alerts

Recall matching is not available yet.

RxMonitor does not yet match Health Canada recalls to individual products — that arrives in a later release. Nothing on this page should be read as confirming that this medication has not been recalled.

Search Health Canada recalls for Riva-Letrozole →

Important:

Information only — this is not medical advice. RxMonitor shows what Health Canada and provincial drug programs have published about authorised products. It does not tell you what to take, whether a medication is right for you, or what dose to use.

Always talk to a pharmacist or physician about your own medication, and never start, stop or change one based on what you read here.